Cargando…

Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms

CONTEXT: The detection of low‐level persistent or relapsed B‐cell neoplasms, particularly post‐therapy, can be challenging, often requiring multiple testing modalities. OBJECTIVE: Here we investigate the utility of CD19‐based selection of neoplastic B‐cells (CD19S) as an enrichment strategy to impro...

Descripción completa

Detalles Bibliográficos
Autores principales: Parrott, Andrew M., Murty, Vundavalli V., Walsh, Caitlin, Christiano, Alecia, Bhagat, Govind, Alobeid, Bachir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026942/
https://www.ncbi.nlm.nih.gov/pubmed/33724696
http://dx.doi.org/10.1002/cam4.3853
_version_ 1783675730612191232
author Parrott, Andrew M.
Murty, Vundavalli V.
Walsh, Caitlin
Christiano, Alecia
Bhagat, Govind
Alobeid, Bachir
author_facet Parrott, Andrew M.
Murty, Vundavalli V.
Walsh, Caitlin
Christiano, Alecia
Bhagat, Govind
Alobeid, Bachir
author_sort Parrott, Andrew M.
collection PubMed
description CONTEXT: The detection of low‐level persistent or relapsed B‐cell neoplasms, particularly post‐therapy, can be challenging, often requiring multiple testing modalities. OBJECTIVE: Here we investigate the utility of CD19‐based selection of neoplastic B‐cells (CD19S) as an enrichment strategy to improve the detection rate of cytogenetic abnormalities in post‐therapy samples of B‐cell neoplasms, especially those with low‐level disease. DESIGN: In a cohort largely comprised of post‐therapy B‐ALL and CLL samples, we performed fluorescence in situ hybridization (FISH) analysis on CD19‐selected cells (CD19S FISH) in 128 specimens from 88 patients, and on non‐selected cells (NS FISH) in a subset of cases. The FISH findings were compared with the concurrent flow cytometry (FC) results in all samples and molecular analysis in a subset. RESULTS: CD19S FISH was able to detect cytogenetic aberrations in 86.0% of post‐therapy samples with evidence of disease as determined by routine or MRD FC, compared to 59.1% of samples by NS FISH. CD19S FISH detected significantly higher percentages of positive cells compared to NS FISH (p < 0.001). Importantly, CD19S FISH enabled the detection of emergent subclones (clonal evolution) associated with poor prognosis. CONCLUSIONS: CD19S FISH can be useful in daily diagnostic practice. Compared to NS FISH, CD19S FISH is quantitatively and qualitatively superior for the detection of cytogenetic aberrations in B‐cell neoplasms, which are important for risk stratification and optimal management of patients with B‐cell neoplasms, especially in the relapsed setting. Although CD19S FISH has a diagnostic sensitivity inferior to that of MRD FC, the sensitivity of this modality is comparable to routine FC for the evaluation of low‐level disease in the post‐therapy setting. Moreover, CD19S samples are invaluable for additional molecular and genetic analyses.
format Online
Article
Text
id pubmed-8026942
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80269422021-04-13 Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms Parrott, Andrew M. Murty, Vundavalli V. Walsh, Caitlin Christiano, Alecia Bhagat, Govind Alobeid, Bachir Cancer Med Clinical Cancer Research CONTEXT: The detection of low‐level persistent or relapsed B‐cell neoplasms, particularly post‐therapy, can be challenging, often requiring multiple testing modalities. OBJECTIVE: Here we investigate the utility of CD19‐based selection of neoplastic B‐cells (CD19S) as an enrichment strategy to improve the detection rate of cytogenetic abnormalities in post‐therapy samples of B‐cell neoplasms, especially those with low‐level disease. DESIGN: In a cohort largely comprised of post‐therapy B‐ALL and CLL samples, we performed fluorescence in situ hybridization (FISH) analysis on CD19‐selected cells (CD19S FISH) in 128 specimens from 88 patients, and on non‐selected cells (NS FISH) in a subset of cases. The FISH findings were compared with the concurrent flow cytometry (FC) results in all samples and molecular analysis in a subset. RESULTS: CD19S FISH was able to detect cytogenetic aberrations in 86.0% of post‐therapy samples with evidence of disease as determined by routine or MRD FC, compared to 59.1% of samples by NS FISH. CD19S FISH detected significantly higher percentages of positive cells compared to NS FISH (p < 0.001). Importantly, CD19S FISH enabled the detection of emergent subclones (clonal evolution) associated with poor prognosis. CONCLUSIONS: CD19S FISH can be useful in daily diagnostic practice. Compared to NS FISH, CD19S FISH is quantitatively and qualitatively superior for the detection of cytogenetic aberrations in B‐cell neoplasms, which are important for risk stratification and optimal management of patients with B‐cell neoplasms, especially in the relapsed setting. Although CD19S FISH has a diagnostic sensitivity inferior to that of MRD FC, the sensitivity of this modality is comparable to routine FC for the evaluation of low‐level disease in the post‐therapy setting. Moreover, CD19S samples are invaluable for additional molecular and genetic analyses. John Wiley and Sons Inc. 2021-03-15 /pmc/articles/PMC8026942/ /pubmed/33724696 http://dx.doi.org/10.1002/cam4.3853 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Parrott, Andrew M.
Murty, Vundavalli V.
Walsh, Caitlin
Christiano, Alecia
Bhagat, Govind
Alobeid, Bachir
Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
title Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
title_full Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
title_fullStr Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
title_full_unstemmed Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
title_short Interphase fluorescence in situ hybridization analysis of CD19‐selected cells: Utility in detecting disease in post‐therapy samples of B‐cell neoplasms
title_sort interphase fluorescence in situ hybridization analysis of cd19‐selected cells: utility in detecting disease in post‐therapy samples of b‐cell neoplasms
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026942/
https://www.ncbi.nlm.nih.gov/pubmed/33724696
http://dx.doi.org/10.1002/cam4.3853
work_keys_str_mv AT parrottandrewm interphasefluorescenceinsituhybridizationanalysisofcd19selectedcellsutilityindetectingdiseaseinposttherapysamplesofbcellneoplasms
AT murtyvundavalliv interphasefluorescenceinsituhybridizationanalysisofcd19selectedcellsutilityindetectingdiseaseinposttherapysamplesofbcellneoplasms
AT walshcaitlin interphasefluorescenceinsituhybridizationanalysisofcd19selectedcellsutilityindetectingdiseaseinposttherapysamplesofbcellneoplasms
AT christianoalecia interphasefluorescenceinsituhybridizationanalysisofcd19selectedcellsutilityindetectingdiseaseinposttherapysamplesofbcellneoplasms
AT bhagatgovind interphasefluorescenceinsituhybridizationanalysisofcd19selectedcellsutilityindetectingdiseaseinposttherapysamplesofbcellneoplasms
AT alobeidbachir interphasefluorescenceinsituhybridizationanalysisofcd19selectedcellsutilityindetectingdiseaseinposttherapysamplesofbcellneoplasms